BidaskClub upgraded shares of Crispr Therapeutics (NASDAQ:CRSP) from a hold rating to a buy rating in a research note published on Thursday, January 4th.
A number of other research firms have also recently weighed in on CRSP. Cann reissued a hold rating on shares of Crispr Therapeutics in a research note on Sunday, December 10th. SunTrust Banks reissued a hold rating and issued a $16.00 target price on shares of Crispr Therapeutics in a research note on Friday, November 10th. Piper Jaffray Companies initiated coverage on shares of Crispr Therapeutics in a research note on Friday, December 22nd. They issued an overweight rating on the stock. Barclays reissued a buy rating and issued a $29.00 target price on shares of Crispr Therapeutics in a research note on Friday, September 8th. Finally, Oppenheimer reissued a hold rating on shares of Crispr Therapeutics in a research note on Thursday, December 21st. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $22.81.
Crispr Therapeutics (CRSP) traded up $1.41 during mid-day trading on Thursday, hitting $27.18. 169,981 shares of the company traded hands, compared to its average volume of 1,389,300. The firm has a market cap of $1,060.00 and a price-to-earnings ratio of -84.94. Crispr Therapeutics has a 1-year low of $11.63 and a 1-year high of $28.50.
In other news, Director Kurt Von Emster sold 92,337 shares of the company’s stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $26.96, for a total transaction of $2,489,405.52. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Tyler Dylan-Hyde sold 31,000 shares of the company’s stock in a transaction that occurred on Friday, December 29th. The stock was sold at an average price of $22.72, for a total transaction of $704,320.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,168,504 shares of company stock worth $42,538,573. Company insiders own 39.98% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN lifted its holdings in Crispr Therapeutics by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after buying an additional 6,560 shares during the period. Capital Investment Advisory Services LLC acquired a new position in Crispr Therapeutics in the third quarter valued at approximately $193,000. Ark Investment Management LLC acquired a new position in Crispr Therapeutics in the second quarter valued at approximately $206,000. Moloney Securities Asset Management LLC bought a new stake in Crispr Therapeutics in the third quarter valued at approximately $235,000. Finally, Bank of New York Mellon Corp bought a new stake in Crispr Therapeutics in the third quarter valued at approximately $288,000. Institutional investors and hedge funds own 24.52% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://stocknewstimes.com/2018/01/11/crispr-therapeutics-crsp-lifted-to-buy-at-bidaskclub.html.
About Crispr Therapeutics
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.